• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 27, 2016

View Archived Issues

Other news to note

Auven Therapeutics Management LLLP, of St. Thomas, U.S. Virgin Islands, said it executed agreements to sell 100 percent of Ocular Technologies Sarl, a wholly owned subsidiary through which all rights to Seciera (OTX-101) are held, to a subsidiary of Sun Pharmaceuticals Industries Ltd., of Mumbai, India. Read More

Financings

Ritter Pharmaceuticals Inc., of Los Angeles, said it priced an underwritten public offering of 2.12 million shares of its common stock at $2.35 each. Read More

In the clinic

Eurocrine Vaccines AB, of Solna, Sweden, said it started a phase I/II trial of its quadrivalent influenza vaccine, Immunose Flu, a nose-drop formulation based on the company's Endocine technology and inactivated split antigens. Read More

Earnings

Biogen Inc., of Cambridge, Mass., reported total revenues of $3 billion in the third quarter of 2016 financial results, a 6 percent increase over the same quarter in the prior year. Read More

Regulatory front

The city of Chicago has amended its complaint against several biopharma companies, alleging that their marketing of prescription opioids for chronic pain violated local and state law while opening "the floodgates of opioid use and abuse" and spurring a resurgence in heroin use. Read More

ADME-Tox too, please: Evotec paying $68M for Cyprotex

DUBLIN – Evotec AG is committing about half of its cash resources to acquire Cyprotex plc in an all-cash deal valued at £55.36 million ($67.5 million), which will add a high-throughput ADME-Tox platform to its preclinical drug discovery research service offerings. Read More

IV gene editing delivery cures beta thalassemia in mice

As gene editing of blood stem cells is progressing toward clinical application, one question has been how to make the technology simple and cheap enough to make it a realistic option for the large numbers of patients who could potentially benefit. Read More

CFDA reforms deepen to accelerate innovation

SUZHOU, China – Ruyi He, chief scientist of the CFDA and the Centre for Drug Evaluation (CDE), outlined the government's commitment to streamline and speed up the review process for innovative drugs, sharing support for more dynamic communication between reviewers and sponsors. Read More

Vertex phase II effort in CF with triples makes ripples, opinion mismatch

Third-quarter results from Vertex Pharmaceuticals Inc. didn't much rattle Wall Street, but some onlookers made known their uncertainty about the company's plan to start two phase II studies with next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and Vertex's Kalydeco (ivacaftor) in cystic fibrosis (CF). Read More

Oncogenex sees bladder cancer benefit in apatorsen

Oncogenex Pharmaceuticals Inc. reported that a combination of its lead anticancer candidate apatorsen and the chemotherapy docetaxel met the primary endpoint of overall survival in the investigator-sponsored phase II Borealis-2 trial, reducing the risk of death for metastatic bladder cancer patients who failed initial therapy by 20 percent vs. treatment with docetaxel alone (hazard ratio (HR) of 0.80, 95 percent confidence interval: 0.65-0.98; p = 0.078). Read More

Biopharma supplants med tech for top 2017 health care innovations

Medical technology may have scored just as many hits on the Cleveland Clinic's 2017 Top 10 list of medical innovations, but biopharma won the race to the top, taking the top four spots among breakthroughs expected in the coming year. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe